'Patients can’t wait – swift action and access are the only possible moves from here'

Rare Cancers Australia has expressed deep frustration at the latest decisions of the Pharmaceutical Benefits Advisory Committee, which late last week rejected one proposal for pan-tumour immunotherapy access and deferred another. …